In 2015 the European Respiratory Society (ERS) and the American Thoracic Society (ATS) “Task Force on Undifferentiated Forms of Connective Tissue Disease-associ-ated Interstitial Lung Disease” proposed classification criteria for a new research category defined as “Interstitial Pneumonia with Autoimmune Features” (IPAF), to uniformly de-fine patients with interstitial lung disease (ILD) and features of autoimmunity, without a definite connective tissue disease. These classification criteria were based on a variable combination of features obtained from three domains: a clinical domain consisting of extra-thoracic features, a serologic domain with specific autoantibodies, and a morphologic domain with imaging patterns, histopathological findings, or multicompartment in-volvement. Features suggesting a systemic vasculitis were excluded. Since publication of ERS/ATS IPAF research criteria, various retrospective studies have been published focusing on prevalence; clinical, morphological, and serological features; and prognosis of these patients showing a broad heterogeneity in the results. Recently, two prospective, cohort studies were performed, confirming the existence of some peculiarities for this clinical entity and the possible progression of IPAF to a defined connective tissue disease (CTD) in about 15% of cases. Moreover, a non-specific interstitial pneumonia pattern, an anti-nuclear antibody positivity, and a Raynaud phenomenon were the most common findings. In comparison with idiopathic pulmonary fibrosis (IPF), IPAF patients showed a better performance in pulmonary function tests and less necessity of oxygen delivery. However, at this stage of our knowledge, we believe that further prospective studies, possibly derived from multicenter cohorts and through randomized control trials, to further validate the proposed classification criteria are needed.

Interstitial pneumonia with autoimmune features: Why rheumatologist–pulmonologist collaboration is essential / Sebastiani, M.; Faverio, P.; Manfredi, A.; Cassone, G.; Vacchi, C.; Stainer, A.; Pozzi, M. R.; Salvarani, C.; Pesci, A.; Luppi, F.. - In: BIOMEDICINES. - ISSN 2227-9059. - 9:1(2021), pp. 1-15. [10.3390/biomedicines9010017]

Interstitial pneumonia with autoimmune features: Why rheumatologist–pulmonologist collaboration is essential

Sebastiani M.;Manfredi A.;Cassone G.;Vacchi C.;Salvarani C.;
2021-01-01

Abstract

In 2015 the European Respiratory Society (ERS) and the American Thoracic Society (ATS) “Task Force on Undifferentiated Forms of Connective Tissue Disease-associ-ated Interstitial Lung Disease” proposed classification criteria for a new research category defined as “Interstitial Pneumonia with Autoimmune Features” (IPAF), to uniformly de-fine patients with interstitial lung disease (ILD) and features of autoimmunity, without a definite connective tissue disease. These classification criteria were based on a variable combination of features obtained from three domains: a clinical domain consisting of extra-thoracic features, a serologic domain with specific autoantibodies, and a morphologic domain with imaging patterns, histopathological findings, or multicompartment in-volvement. Features suggesting a systemic vasculitis were excluded. Since publication of ERS/ATS IPAF research criteria, various retrospective studies have been published focusing on prevalence; clinical, morphological, and serological features; and prognosis of these patients showing a broad heterogeneity in the results. Recently, two prospective, cohort studies were performed, confirming the existence of some peculiarities for this clinical entity and the possible progression of IPAF to a defined connective tissue disease (CTD) in about 15% of cases. Moreover, a non-specific interstitial pneumonia pattern, an anti-nuclear antibody positivity, and a Raynaud phenomenon were the most common findings. In comparison with idiopathic pulmonary fibrosis (IPF), IPAF patients showed a better performance in pulmonary function tests and less necessity of oxygen delivery. However, at this stage of our knowledge, we believe that further prospective studies, possibly derived from multicenter cohorts and through randomized control trials, to further validate the proposed classification criteria are needed.
9
1
1
15
Interstitial pneumonia with autoimmune features: Why rheumatologist–pulmonologist collaboration is essential / Sebastiani, M.; Faverio, P.; Manfredi, A.; Cassone, G.; Vacchi, C.; Stainer, A.; Pozzi, M. R.; Salvarani, C.; Pesci, A.; Luppi, F.. - In: BIOMEDICINES. - ISSN 2227-9059. - 9:1(2021), pp. 1-15. [10.3390/biomedicines9010017]
Sebastiani, M.; Faverio, P.; Manfredi, A.; Cassone, G.; Vacchi, C.; Stainer, A.; Pozzi, M. R.; Salvarani, C.; Pesci, A.; Luppi, F.
File in questo prodotto:
File Dimensione Formato  
sebastiani IPAF review 2020.pdf

Open access

Descrizione: Main document
Tipologia: Versione pubblicata dall'editore
Dimensione 289.08 kB
Formato Adobe PDF
289.08 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1229965
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 9
social impact